Literature DB >> 34363901

An Overview of Phase 2 Clinical Trial Designs.

Pedro A Torres-Saavedra1, Kathryn A Winter2.   

Abstract

Clinical trials are studies to test new treatments in humans. Typically, these treatments are evaluated over several phases to assess their safety and efficacy. Phase 1 trials are designed to evaluate the safety and tolerability of a new treatment, typically with a small number of patients (eg, 20-80), generally spread across several dose levels. Phase 2 trials are designed to determine whether the new treatment has sufficiently promising efficacy to warrant further investigation in a large-scale randomized phase 3 trial, as well as to further assess safety. These studies usually involve a few hundred patients. This article provides an overview of some of the most commonly used phase 2 designs for clinical trials and emphasizes their critical elements and considerations. Key references to some of the most commonly used phase 2 designs are given to allow the reader to explore in more detail the critical aspects when planning a phase 2 trial. A comparison of 3 potential designs in the context of the NRG-HN002 trial is presented to complement the discussion about phase 2 trials.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34363901      PMCID: PMC8688307          DOI: 10.1016/j.ijrobp.2021.07.1700

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  41 in total

Review 1.  Stopping rules for phase II studies.

Authors:  N Stallard; J Whitehead; S Todd; A Whitehead
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

2.  Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteria.

Authors:  G Heller
Journal:  Ann Oncol       Date:  2015-08-07       Impact factor: 32.976

Review 3.  Alternate endpoints for screening phase II studies.

Authors:  Neesha Dhani; Dongsheng Tu; Daniel J Sargent; Lesley Seymour; Malcolm J Moore
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

4.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

5.  Single-Arm Phase II Trials of Combination Therapies: A Review of the CTEP Experience 2008-2017.

Authors:  Jared C Foster; Boris Freidlin; Charles A Kunos; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2020-02-01       Impact factor: 13.506

6.  Window of opportunity trials in head and neck cancer.

Authors:  Janice L Farlow; Andrew C Birkeland; Paul L Swiecicki; J Chad Brenner; Matthew E Spector
Journal:  J Cancer Metastasis Treat       Date:  2019-03-18

Review 7.  An overview of precision oncology basket and umbrella trials for clinicians.

Authors:  Jay J H Park; Grace Hsu; Ellie G Siden; Kristian Thorlund; Edward J Mills
Journal:  CA Cancer J Clin       Date:  2020-02-07       Impact factor: 508.702

Review 8.  Synthetic and External Controls in Clinical Trials - A Primer for Researchers.

Authors:  Kristian Thorlund; Louis Dron; Jay J H Park; Edward J Mills
Journal:  Clin Epidemiol       Date:  2020-05-08       Impact factor: 4.790

9.  Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).

Authors:  Sue S Yom; Pedro Torres-Saavedra; Jimmy J Caudell; John N Waldron; Maura L Gillison; Ping Xia; Minh T Truong; Christina Kong; Richard Jordan; Rathan M Subramaniam; Min Yao; Christine H Chung; Jessica L Geiger; Jason W Chan; Brian O'Sullivan; Dukagjin M Blakaj; Loren K Mell; Wade L Thorstad; Christopher U Jones; Robyn N Banerjee; Christopher Lominska; Quynh-Thu Le
Journal:  J Clin Oncol       Date:  2021-01-28       Impact factor: 44.544

10.  Evaluating many treatments and biomarkers in oncology: a new design.

Authors:  Richard Kaplan; Timothy Maughan; Angela Crook; David Fisher; Richard Wilson; Louise Brown; Mahesh Parmar
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.